Targeting nicotinamide N-methyltransferase overcomes resistance to EGFR-TKI in non-small cell lung cancer cells

Targeting nicotinamide N-methyltransferase overcomes resistance to EGFR-TKI in non-small cell lung cancer cells

Abstract Activating mutations of epidermal growth factor receptor (EGFR) contributes to the progression of non-small cell lung cancer (NSCLC). EGFR tyrosine kinase inhibitor (TKI)-targeted therapy has become the standard treatment for NSCLC patients with EGFR-mutations. However, acquired resistance...

Full description

Bibliographic Details
Main Authors: Jun Wang, Xi Liu, Yuanfeng Huang, Pan Li, Minqiang Yang, Shanshan Zeng, Danyang Chen, Qian Wang, Hao Liu, Kai Luo, Jin Deng
Format: Article
Language:English
Published: Nature Publishing Group 2022-04-01
Series:Cell Death Discovery
Online Access:https://doi.org/10.1038/s41420-022-00966-x

Internet

https://doi.org/10.1038/s41420-022-00966-x

Similar Items